With an old approach but new energy, adcs take center stage as promising cancer treatments

With an old approach but new energy, adcs take center stage as promising cancer treatments


Play all audios:


MADRID — If you had to pinpoint one subject that stood out at this year’s European Society for Medical Oncology meeting, a massive conference with thousands of people from 140-some countries


and 2,500 studies presented, it would be a burgeoning type of cancer treatment called antibody-drug conjugates. The conference opened to the news that Merck had signed one of the biggest


licensing deals in industry history — worth up to $22 billion — to partner on three of the compounds from ADC specialist Daiichi Sankyo. GSK followed up with an ADC licensing announcement of


its own (if a much smaller one). Multiple ADC studies were presented at the meeting’s top sessions. ADCs were, in short, the belle of the cancer research ball. The thing is, ADCs are


actually quite an old approach. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS DAILY COVERAGE AND ANALYSIS OF


THE PHARMA INDUSTRY — BY SUBSCRIBING TO STAT+. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe